
Keywords: prostatic neoplasms; androgen antagonists; antineoplastic agents; hormonal; drug related side effects and adverse reactions; risk; ADT; androgen deprivation therapy; AMI; acute myocardial infarction; CADT; continuous ADT; GnRH; gonadotropin-releasing horm